- Home
- PCVX vs BIRK Comparison
PCVX vs BIRK Comparison
Compare PCVX & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCVX | BIRK |
|---|---|---|
| Founded | 2013 | 1774 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.1B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PCVX | BIRK |
|---|---|---|
| Price | $56.10 | $35.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $98.33 | $62.69 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-06-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.71 |
| Revenue Next Year | N/A | $14.21 |
| P/E Ratio | ★ N/A | $17.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $33.06 |
| 52 Week High | $73.82 | $57.39 |
Technical Indicators
Market Signals| Indicator | PCVX | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 39.75 |
| Support Level | $42.30 | N/A |
| Resistance Level | $58.95 | $42.19 |
| Average True Range (ATR) | 2.47 | 1.48 |
| MACD | -0.64 | -0.44 |
| Stochastic Oscillator | 33.46 | 25.26 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.